Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Adam Dubow Sells 4,646 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Adam Dubow sold 4,646 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares of the company’s stock, valued at approximately $473,639.92. This represents a 10.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Day One Biopharmaceuticals Stock Up 1.6 %

Shares of DAWN opened at $12.43 on Friday. Day One Biopharmaceuticals, Inc. has a twelve month low of $11.13 and a twelve month high of $18.07. The firm has a 50 day moving average of $12.37 and a 200 day moving average of $13.47. The company has a market capitalization of $1.25 billion, a P/E ratio of -12.07 and a beta of -1.46.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. The Goldman Sachs Group dropped their target price on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Bank of America decreased their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Needham & Company LLC restated a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. Finally, TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $35.71.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth $27,000. R Squared Ltd purchased a new position in shares of Day One Biopharmaceuticals during the 4th quarter worth $31,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after acquiring an additional 1,002 shares during the last quarter. Quest Partners LLC boosted its stake in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after acquiring an additional 7,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Day One Biopharmaceuticals by 911.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock worth $135,000 after acquiring an additional 9,603 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.